Lucid Capital downgraded Cargo Therapeutics (CRGX) to Neutral from Buy with a price target of $4, down from $34, after the company announced the discontinuation of the Phase 2 FIRCE-1 study investigating firi-cel in relapsed/ refractory patients with large B-cell lymphoma. The firm removed firi-cel from its valuation and reduced Cargo’s earlier pipeline and platform value. It awaits clinical data from pipeline programs before getting more constructive on the shares.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRGX:
- Shares in Cargo Therapeutics Dive after It Scraps Cancer Trial and Slashes Jobs
- Cargo Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Cargo Therapeutics downgraded to Hold from Buy at Truist
- Cargo Therapeutics downgraded to Hold at Truist after Firi-cel disappointment
- Cargo Therapeutics downgraded to Underweight from Overweight at JPMorgan